| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Effect positive change on patients’ lives.
Infor is a multi-national enterprise software company, headquartered in New York City, United States.
Creating Foundational Infrastructure For Web3.0
MOVO - a new way to bank, send/receive money & make payments, regardless of financial background or credit history. Forget about the old ways to bank; today’s world is mobile and so should banking and payments be. MOVO is transforming the traditional w...